Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a specific reporting date of February 11, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2022-02-09 | Ordinary Shares (25p each) | £16.2699 | 144 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 144 shares represents the sum of 10 individual transactions. Most executives acquired 16 shares (8 partnership + 8 matching), while Mr. R. Simard acquired 14 shares (7 partnership + 7 matching).
Material Changes
The filing does not provide comparative data against prior periods or report material changes to the company's financial position or operations. It is a routine disclosure of share plan acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The transactions are standard acquisitions under the Company's Share Reward Plan.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Share Reward Plan, not open market sales or purchases.
- Participants: Transactions involved 10 senior executives, including CEO Emma Walmsley, President of Vaccines & Global Health Richard Connor, and CEO of ViiV Healthcare Daria Waterhouse.
- Valuation: All shares were acquired at a uniform price of £16.2699 per share on February 9, 2022.
- Volume: The total number of shares acquired by all listed insiders in this filing is minimal (144 shares total), indicating these are likely vesting or matching contributions rather than significant capital deployment.